• This award recognises the three best scientific articles published in the field of radiation oncology in 2025 in internationally renowned journals
• The total amount allocated to these prizes is €9,000, distributed as follows: a first prize of €5,000, a second prize of €3,000 and a third prize of €1,000.
• The registration period will close on 17 April 2026 at 11 p.m.

Atrys Health, a medical company specialising in telediagnostic, oncology, pathological anatomy and nuclear medicine services, and the University of Barcelona are opening the application process for participation in the 5th edition of the Personalised Radiotherapy Research Awards, linked to the UB Atrys Chair, created in 2021.

This award recognises the three best scientific articles published during 2025 in prestigious international journals in the field of radiation oncology and aims to recognise excellence and innovation in research, as well as to promote the dissemination of knowledge in a field that is essential for progress in cancer treatment. To be eligible, articles must be authored by Spanish research groups or research groups from other countries, provided that the first author is affiliated with a Spanish group.

The total amount allocated to these awards is €9,000, distributed as follows: a first prize of €5,000, a second prize of €3,000 and a third prize of €1,000. Interested researchers can find all the information about applying for the awards at the following link, and the registration deadline is 11 p.m. on 17 April 2026.

The entries will be evaluated by the Chair’s management on behalf of the University of Barcelona, the Chair’s deputy management on behalf of ATRYS, the president of the Spanish Society of Radiation Oncology (SEOR) and the management of the Institute for Research in Radiation Oncology (IRAD). The selected proposals will be notified to the rector, who will issue the decision on the awarding of prizes, which will be published on the University of Barcelona’s website. The awards ceremony will take place at the SEOR Symposium, to be held in Alicante from 3 to 5 June 2026, where the winning researchers will present their projects.

• Teragnosis in paediatric oncology represents a pioneering clinical advance in Spain and Europe, where very few centres offer this therapeutic option.

• This precision therapy makes it possible to treat some of the most common paediatric tumours—neuroblastoma, medulloblastoma, and thyroid cancer—with maximum effectiveness on tumour cells and minimal impact on healthy tissue.

• The Sant Joan de Déu Hospital applies this technique in its day hospital, in rooms with sea views and family support, allowing children to return home the same day.

Atrys Health, a medical company specialising in telediagnostic, oncology, pathological anatomy and nuclear medicine services, and the Pediatric Cancer Centre Barcelona (PCCB) at Sant Joan de Déu Hospital are expanding their capacity to apply teragnosis after receiving authorisation to open two new rooms specifically designed for this pioneering therapy against childhood cancer. This step represents a significant clinical advance in Spain and Europe, where very few hospitals currently offer this therapeutic option.

Teragnosis is an innovative precision medicine technique that combines diagnosis and treatment in a single strategy, using the same molecule to detect the tumour and administer selectively targeted therapy. This approach allows action to be taken exclusively on tumour cells without damaging healthy tissue, a crucial advantage in paediatric oncology, reducing the long-term adverse effects of conventional treatments.

This therapeutic modality is particularly effective in combating some of the most common paediatric tumours: neuroblastoma, the most frequent extracranial solid tumour in childhood, with around 100 new cases per year in Spain; medulloblastoma, one of the most common aggressive tumours of the central nervous system in paediatrics; and childhood thyroid cancer, the incidence of which has increased in recent decades.

‘The authorisation to use teragnosis in paediatric patients is a milestone for Atrys. This technique is still rarely used in Europe, placing us at the forefront of precision medicine. Its value lies in maximising therapeutic efficacy with minimal aggressiveness for children,’ says Isabel Roca, Director of Nuclear Medicine at Atrys and Head of the Nuclear Medicine Service at Sant Joan de Déu Hospital’.

Facilities and patient experience

To make this new treatment possible, Sant Joan de Déu Hospital has two rooms specifically designed for the administration of theragnosis, as well as a Nuclear Medicine department equipped with state-of-the-art technology (1 PET-CT and 2 SPECT-CT).

The treatment is carried out on an outpatient basis in comfortable rooms with sea views, allowing the child to be accompanied by their family during the six to eight hours of the procedure and to return home the same day.

Research that becomes clinical reality

Atrys and the PCCB at Sant Joan de Déu Hospital have been collaborating for years on international clinical trials in both paediatric cancer diagnosis and paediatric theragnosis, a line of research that is now taking a decisive leap towards real clinical application in Spain. This advance places the centre among the European leaders in paediatric precision medicine and offers new hope for children with cancer and their families.

• With over 25 years of experience, Dr. Vives will assume the medical direction of this strategic service for the company, reinforcing clinical leadership and quality of care.

• A specialist in radiology, he brings extensive experience in diagnostic imaging and in the implementation and management of teleradiology platforms, combining healthcare activity, clinical leadership and service optimisation.

• The new medical director has an outstanding track record in healthcare at centres such as HM Delfos, Hospital CIMA Sanitas, Grupo Recoletas and Hospital Universitario Quirón Dexeus, among others.

• With this appointment, Atrys consolidates its leadership in Spanish-language telediagnostics, with more than 8.4 million telediagnostics per year.

Atrys, a medical company specialising in telediagnostic, oncology, pathological anatomy and nuclear medicine services, has announced the appointment of Dr Pep Vives Roura as the new medical director of its teleradiology department. With more than 25 years of experience as a radiologist, both in healthcare and in the management and direction of radiology services, Dr. Vives assumes the medical direction of this strategic service for the company, reinforcing clinical leadership and healthcare quality.l.

With this appointment, Atrys will continue to position itself as a leader in remote diagnostic imaging, consolidating its leadership in the Spanish-speaking world with more than 8.4 million online diagnoses per year.

The company currently provides teleradiology services to a wide network of public and private hospitals in both Spain and Latin America. This activity represents one of the group’s main lines of business, integrated within the Diagnostics area, which at the end of the third quarter of 2025 recorded revenues of €51.5 million, with growth of 5.9% compared to the same period last year.

‘Teleradiology is one of Atrys’ strategic growth areas and a key pillar for offering fast, accurate and accessible diagnosis. The addition of Dr Pep Vives allows us to continue strengthening this service, with the clinical leadership necessary to maintain the highest quality standards and support our international expansion,’ said Marian Isach, CEO of Atrys.

In his new role, Dr Vives will lead key functions for the company, such as issuing second radiological opinions in complex cases, providing clinical advice to client centres, medical supervision of the teleradiology service and coordination of the medical team. He will also participate in the definition and updating of clinical protocols, internal audits and patient quality and safety programmes, as well as in the evaluation and validation of new professionals.

‘It is an honour to join a project like Atrys, which is committed to medical excellence and technological innovation to improve patient care. Teleradiology offers an essential tool for responding to the challenges of the healthcare system, ensuring equity and greater agility in access to diagnosis, regardless of the patient’s geographical location,’ said Dr Pep Vives.

With a degree in Medicine from the Autonomous University of Barcelona and a specialisation in Radiology, Dr. Vives has accumulated solid experience in various fields of Diagnostic Imaging, combining healthcare activity with the organisation and optimisation of Radiology services. He has outstanding experience in the implementation, management and quality control of teleradiology platforms and has led multidisciplinary teams focused on operational efficiency and excellence in care. The new medical director has extensive healthcare experience at centres such as HM Delfos, Hospital CIMA Sanitas, Grupo Recoletas and Hospital Universitario Quirón Dexeus, among others. He currently combines his clinical work with teaching at universities and training programmes.

• Valcaneras será responsável pela implementação da estratégia corporativa da Atrys e pela coordenação das suas operações internacionais, reportando diretamente a Marian Isach, CEO da empresa, e integrando o Comité de Gestão do grupo.
• With over 20 years of experience in operational management, medical insurance, international expansion and digital transformation, Valcaneras brings a solid knowledge of the healthcare sector, both in hospital environments and in large healthcare companies.

Atrys Health, a medical company specialising in telediagnostic, oncology, pathological anatomy and nuclear medicine services, has announced the appointment of Íñigo Valcaneras as its new Director of Operations. With more than 20 years of experience in the healthcare sector, Valcaneras will be responsible for integrating and coordinating national and international operations, under a model that ensures excellence in care and rigorous cost control. He will report directly to Marian Isach, the company’s Chief Executive Officer, and will join the group’s Management Committee.

In his new role, Valcaneras will lead the comprehensive supervision of the group’s activities in all countries, with the aim of improving operational efficiency, optimising structures and ensuring the effective use of resources in line with the objectives of growth, sustainability and profitability.

“Atrys is entering a new phase of consolidation and expansion of its core businesses. Íñigo’s appointment reflects our ambition to take another step forward in integrating our operations, gaining agility and continuing to strengthen a model that combines technological innovation with quality care. His track record and international experience will help us turn that vision into a tangible reality in all the countries where we operate,” said Marian Isach, CEO of Atrys.

Valcaneras has solid experience in operational management, medical insurance, international expansion and digital transformation, both in the hospital sector and in large companies in the healthcare sector. Before joining Atrys, he was Director of Operations for the hospitals and social-health centres of emeis, a leading global healthcare company. Previously, he worked for ten years at the University Clinic of Navarra, where he managed the Madrid headquarters and the International Patient Sales Office, promoting its business in Latin America.

‘I am starting this new phase with great enthusiasm, in a company that is a leader in telemedicine, technological innovation and cancer treatment. Atrys is experiencing significant international growth, and my goal is to support this development with a solid, efficient and scalable operating model, without ever losing sight of service quality and our customers’ experience,’ said Íñigo Valcaneras.

The new Director of Operations at Atrys has been a member of the Board of Directors of the Spanish Private Healthcare Alliance (ASPE) and President of the Spanish Health Tourism Cluster (Spaincares). He has a degree in Economics from the University of Navarra, an MBA from IESE and a digital business programme from ISDI.

• The company, which specialises in precision medical diagnosis and treatment, will take over management of the service at the new Vithas Barcelona Hospital, Vithas Lleida Hospital and Garraf Medical Centre.
• This new agreement consolidates the relationship between Atrys and Vithas, which already collaborate in the provision of teleradiology and oncology services
• The service will be supported by the use of digital pathology, which contributes to improving diagnostic quality and efficiency, as well as speeding up response times in the face of growing demand for care

Atrys Health, a global company specialising in precision medical diagnosis and treatment, a leader in telemedicine and cancer treatment, has reached an agreement with the Vithas hospital group to manage the Pathological Anatomy service at three of its centres in Catalonia: the new Vithas Barcelona Hospital (Esplugues de Llobregat), the Vithas Lleida Hospital and the Garraf Medical Centre (Vilanova i la Geltrú). Overall, Vithas has a network of 22 hospitals and 39 medical and healthcare centres in 14 provinces, making the company a leader in Spanish healthcare.

The collaboration covers the provision of comprehensive services, including assistance with intraoperative biopsies, Mohs surgeries and other procedures performed directly at the centre, such as image-guided punctures, as well as the active participation of specialists in clinical committees. Atrys will have pathologists physically present at the centres, ensuring close care and effective coordination with the medical and surgical teams.

The healthcare model implemented by Atrys is based on medical subspecialisation, which allows each case to be assessed by professionals with specific experience in different fields of pathology. This approach enables the provision of accurate and specialised care, reinforcing the quality of service and confidence in clinical decisions.

The service will be supported by the use of digital pathology, which provides access to a wide network of pathology professionals who are experts in their fields, enabling cases to be shared in real time and care processes to be optimised, significantly improving response times and the issuance of diagnostic reports. In addition, the integration between the two entities ensures complete traceability of samples and clinical information. This digital environment opens the door to the progressive incorporation of advanced tools, such as artificial intelligence, contributing to greater efficiency and agility in response times.

This new agreement strengthens the collaboration between Atrys and Vithas, which already work together on teleradiology services, as well as in the field of oncology at two of the hospital group’s centres. With this alliance, Atrys consolidates its presence in Catalonia and takes another step forward in its commitment to transforming medical diagnosis with innovative, accurate and accessible solutions.

‘This agreement with Vithas reinforces our commitment to precision diagnosis, based on medical subspecialisation and digitalisation. We are proud to consolidate our collaboration with Vithas and to continue expanding our presence in Catalonia, contributing to more efficient and personalised healthcare for patients,’ says Marian Isach, CEO of Atrys.

• Oncology (+21.2%) and Diagnostics (+5.9%) lead Atrys’ growth and strengthen its position in precision medicine

• During the first nine months of 2025, the company inaugurated the Institute of Advanced Oncology (IOA) Madrid and opened two new medical oncology centres in Mexico

• The funds obtained from thesale of ASPY will be used to reduce the Group’s financial debtto bring the debt ratio to around 1.0x(from 3.7x), with annual savings in financial expenses of around €13million  

Atrys, a global healthtech company providing precision medical diagnosis and treatment services, a leader in telemedicine and cancer treatment, has announced its results for the third quarter of 2025, reflecting solid overall growth in turnover and consolidation in its key business areas: Oncology and Diagnostics.

During the first nine months of the year, the company increased its revenue by 8.2% compared to the same period in 2024, reaching 168.4 million euros. This growth is mainly supported by the positive performance of its most strategic business lines.

The gross margin on turnover stands at 62.5%, slightly below the 66% recorded in the same period last year, due to the greater weight of the Oncology and Diagnostics areas in the company’s overall turnover.

Adjusted EBITDA fell by 10.5% to €27.9 million, mainly due to the reduction in revenue from R&D project grants, which fell from €4.5 million in 2024 to €0.3 million this year. Excluding the impact of the reduction in revenue from R&D project grants, adjusted EBITDA increased by +3.5%.

During the first nine months of 2025, the company inaugurated the Institute of Advanced Oncology (IOA) in Madrid and opened two new medical oncology centres in Mexico.

Adjusted operating cash flow fell by 20.2% to £18.5 million, due to the combined effect of lower grant income and increased CAPEX for the opening of new centres. Without these effects, operating cash flow would have increased by 15.2%.

Oncology recorded growth of 21.2% and Diagnostics 5.9%, with a notable boost from the Genetics área

The company’s results for the first nine months of 2024 reflect positive performance in all business areas, with a notable boost from the Oncology segment, whose turnover grew by 21.2% to €55.254 billion. This growth was particularly strong in Mexico, with an increase of 63.1% thanks to the opening of new oncology centres, and in Spain, with 21.6%, driven by the excellent ramp-up of the IOA Madrid radiotherapy centre and high demand for the Medical Oncology service.

The Diagnostics area, meanwhile, grew by 5.9% to €51.492 billion. In this segment, the Pathology and Genetics Laboratories area stood out, experiencing growth of 19.3% due to strong demand for HPV tests in the Genetics area, which saw a notable increase in revenue of 111.9%.

The sale of ASPY significantly improves the Group’s debt and reinforces its core business strategy

On 4 November, Atrys announced the agreement to sell ASPY to Grupo Echevarne for €145 million, subject to regulatory approval and the approval of the General Shareholders’ Meeting, which will take place on 19 December. The funds obtained will be used to reduce the Group’s financial debt to bring the debt ratio (Net Financial Debt/Adjusted EBITDA) to around 1.0x (from 3.7x), with annual savings in financial expenses of around €13 million. Excluding the prevention area (ASPY) from the Atrys Group’s scope, pro forma LTM turnover will amount to €142.6 million and the Group’s adjusted EBITDA to €28.1 million. Pro forma organic growth in LTM turnover will increase from the current +8.2% to +13.4%. 

Marian Isach, CEO of the company, stated that “The sustained growth in our turnover reflects the strength of our strategic areas, Oncology and Diagnostics, which continue to consolidate their position as the core of our model. We are moving towards becoming a more agile, specialised company with an increasingly solid international presence, especially in Latin America. The divestment of ASPY will allow us to focus our resources on businesses with greater potential, drive innovation and generate greater value for our customers and shareholders”.

• The presentation of this fourth edition of the awards, which recognise scientific excellence and innovation in the field of oncology, took place within the framework of the SEOR 2025 Symposium
• The award-winning works, published in prestigious international journals, explore new applications of FLASH radiotherapy, the immunological effects of low doses of radiation, and the use of blood biomarkers to predict therapeutic response in metastatic lung cancer.

The UB-Atrys Chair in Personalised Radiotherapy, promoted by Atrys Health and the University of Barcelona, has presented awards to the three best scientific publications of the year in the field of radiation oncology, selected for their excellence, innovation and contribution to the advancement of cancer therapies. The presentation of this fourth edition of the awards took place within the framework of the SEOR 2025 Symposium, which brings together leading national and international specialists in Salamanca under the slogan Innovation and new perspectives in radiation oncology.

The session was opened by Dr Antonio J. Conde Moreno, head of Radiation Oncology at La Fe Hospital in Valencia, with a presentation on new strategies in stereotactic body radiation therapy (SBRT) and combination therapies. This was followed by the awards ceremony, moderated by Dr Ferran Guedea, director of the Chair and head of Radiation Oncology at the ICO, together with Dr Marco Panichi, medical director of Oncology at Atrys and co-director of the Chair.

In this fourth edition, the first prize, worth €5,000, was awarded to Immaculada Martínez Rovira, from the Autonomous University of Barcelona, for her work on infrared spectroscopy applied to FLASH radiotherapy. The second prize, worth €3,000, went to Ignacio Melero, from the University Clinic of Navarra, for his research on the effects of low doses of ionising radiation and their relationship with the release of extracellular neutrophil traps. The third prize, worth €1,000, went to Juan Zafra Martín, from the Virgen de la Victoria University Clinical Hospital in Malaga, for his study on blood biomarkers to predict the response to the combination of stereotactic radiotherapy and immunotherapy in metastatic lung cancer.

The event was closed by Dr. Víctor Gonzalez-Rumayor, director of Research & Data Intelligence at Atrys, and Dr. Ferran Guedea, head of Radiation Oncology at the Catalan Institute of Oncology and director of the UB Atrys Chair. During their speeches, both emphasised the need to continue promoting research and strengthening collaboration between academic institutions, public administrations and clinical entities, with the aim of advancing towards more precise, innovative and patient-centred oncology.

According to Dr Guedea: ‘These awards recognise the talent and research that drive the evolution of radiation oncology. At the UB-Atrys Chair, we work to bring innovation to clinical practice, and the award-winning projects are an example of how science can transform cancer treatment.’

Dr. Víctor Gonzalez-Rumayor emphasised Atrys’ commitment to developing innovative solutions in radiotherapy: “At Atrys, we are committed to precision medicine driven by clinical research, technology and talent. Personalised radiotherapy is one of our main strategic lines, and we are proud to contribute to the advancement of research such as that awarded in this edition, which opens up new avenues for treating cancer in a more effective, personalised and sustainable way.”

For her part, Inmaculada Martínez Rovira, winner of the first prize, said, ‘This award is an incentive to continue researching techniques such as FLASH radiotherapy, which opens up new possibilities for more effective and less invasive treatments. Initiatives such as the UB-Atrys Chair are essential for connecting research with real improvements in patient care.’

• The transaction, subject to the relevant regulatory approvals and approval by the General Shareholders’ Meeting, will reduce the leverage ratio (Net Financial Debt/Adjusted EBITDA) from 3.8x to 1.1x and lower annual financial expenses by around €13 million.

Atrys Health has signed a share purchase agreement to transfer 100% of Aspy Global Services S.A.U. (ASPY) to Grupo Echevarne, S.L. for €145 million. The agreement also provides for contingent consideration of up to €5 million if the buyer transfers the asset to a third party within one year after closing for an amount higher than the agreed price.

Completion of the transaction is subject to authorisation from the relevant regulatory authorities and approval by Atrys’ General Shareholders’ Meeting, which will be called in the coming days. Closing is expected in the first quarter of 2026.

The divestment of the prevention business will allow Atrys to concentrate resources on its core precision medical diagnosis and treatment businesses, strengthen its financial position, and accelerate organic growth by focusing on business areas where it holds leadership positions and greater return potential.

The proceeds obtained will be used to reduce the Group’s financial debt, targeting a Net Financial Debt/Adjusted EBITDA ratio of around 1.1x (from 3.8x) and annual savings in financial expenses of around €13 million.

Excluding the prevention area (ASPY) from the Atrys Group perimeter, pro forma LTM Revenue (from October 2024 to September 2025) will amount to €142.5 million and the Group’s Adjusted LTM EBITDA to €28.0 million. Pro forma LTM organic revenue growth will increase from the current +8.2% to +13.4%.

Marian Isach, Chief Executive Officer of Atrys, stated: “This transaction strengthens our balance sheet and enables us to focus on the business areas where we have a clear competitive edge and strong growth traction. With lower financing costs and a leaner structure, we will accelerate investment and innovation while reinforcing our international expansion.”

“ASPY has been key to the Group’s development and we will support an orderly transition. This divestment opens a new stage for Atrys, more focused and with a better growth profile,” added Isach.

• Towards the Future of Hospitals is the fifth title in Health Tech, the first Spanish-language collection specialising in technological innovation in health, medicine and medical care promoted by LID Editorial, with the support of Atrys Health and Sanitas, and edited by Santiago de Torres.
• The author, Jordi Serrano-Pons, analyses disruptive technologies and innovations that are helping to create smart, sustainable hospitals that are connected to patients.
• The event took place at the Ortega-Marañón Foundation in Madrid.

LID Editorial, Atrys and Sanitas presented the book Hacia el futuro de los hospitales (Towards the Future of Hospitals) by Jordi Serrano-Pons at the Ortega Marañón Foundation in Madrid. This is the fifth title in Health Tech, the first Spanish-language collection specialising in technological innovation in health, medicine and medical care.

The work is ‘a look towards the future of hospitals,’ a text very much in line with ‘our commitment to develop, protect and update the legacy of those who came before us,’ said Fernando Bandrés, director of the Gregorio Marañón Study Centre.

Hacia el futuro de los hospitales ‘addresses the challenges facing hospitals from a technological and innovative perspective that is also human,’ prioritising value-based patient care, explained Laura Díez, Communications Manager at LID Editorial. ‘Everything that can and should happen is covered in the book,’ said José Francisco Tomás, president of the Sanitas Research Foundation.

The event featured a round table discussion with Jordi Serrano-Pons, author of the book; Santiago de Torres, director of the Health Tech collection and president of Atrys Health; and Julio Mayol, professor of surgery and scientific director at IdISSC.

• The company improves its turnover driven by the strong performance of the oncology and diagnostics areas, which recorded increases of 16.9% and 9.8%, respectively
• Adjusted EBITDA fell by 13.3% (excluding the extraordinary effects of R&D subsidies, the result shows growth of 3.4%), while gross margin grew by 2.2%
• Atrys grows in all its markets, with particular momentum in Spain and Latin America, where Mexico stands out as a driver of expansion

Atrys Health, a global healthtech company providing precision medical prevention, diagnosis, and treatment services, and a leader in telemedicine and cancer treatment, closed the first half of the year with revenues of €115.8 million, representing an increase of 7.8% over the same period last year. This progress was supported by the strength of the Oncology area (+16.9%) and the positive performance of Diagnostics (+9.8%), both of which consolidated their position as strategic drivers for the company.

Adjusted EBITDA reached €21.9 million, down 13.3% due to the lower contribution from R&D subsidies compared to 2024. Excluding the effect of grants, adjusted EBITDA grew by 3.4%, reflecting the group’s operational strength. Gross margin improved by 2.2% to €73.9 million. Net financial debt remained stable at €163.4 million (+1.3%), with an improvement in financial costs due to the fall in the Euribor.

Meanwhile, adjusted operating cash flow fell by 18.2% compared to the same period last year, to €15.7 million. This decrease is mainly due to lower grant income and increased CAPEX for expansion.

The increase in turnover, the improvement in the cost structure, and the absence of extraordinary impairments led the company to record an operating profit of more than €1 million in the first half of the year, compared to a loss of €5.2 million in the same period in 2024. Atrys also reduced its consolidated loss by 43.3%, reflecting a solid financial performance.

Marian Isach, Atrys, CEO chief executive officer, has pointed out that: “The results for the first half of the year reaffirm the strength of our main business areas, while confirming the great potential for expansion in all our markets, with particular dynamism in Latin America. Our commitment is to continue driving the growth of our core business with a firm commitment to innovation, bringing the most advanced and precise therapies to patients. He added: “These advances are supported by strategic milestones such as the opening of the Institute of Advanced Oncology in Madrid, the expansion of medical oncology in Mexico, and the promotion of telemedicine and genetics in Spain, Portugal, and Latin America”.

Growth drivers: medical oncology, advanced radiotherapy, and genetics

During the first six months of the year, Atrys strengthened its leadership in its strategic areas. In Spain, the Oncology division grew by 21% thanks to new commercial agreements and increased activity, while in Mexico, where the company already operates three medical oncology centers, it achieved a 36% increase, while preparing two new openings in the region in the second half of 2025.

In radiotherapy, and true to its innovative DNA, the company inaugurated the IOA Madrid in June, equipped with the first Varian Edge accelerator in Spain, which introduces innovations such as adaptive radiotherapy and free-breathing radiosurgery, improving efficacy and the patient experience.

In diagnostics, revenues increased to €35.1 million, driven by telemedicine (+6.2%) and strong growth in genetics and pathology (+22.6%). In addition, nuclear medicine increased its sales by 5.7% and obtained authorization to expand its teragnosis service, an innovative personalized therapy that combines diagnosis and treatment in the same molecular target, reducing side effects and increasing precision.

Sustained growth and diversified geographic profile

In the first half of 2025, Atrys consolidated the growth of its core business in all its markets, with notable progress in Spain (+8%, €86.5 million) and Latin America (+8%, €21.4 million). Within the region, Mexico stood out with strong performance (+36%), becoming the company’s second most important market in just three years, alongside growth in Colombia (+12.5%), Chile (+1.6%) and the expansion of medical oncology in Brazil. In Portugal, revenues increased by 7.3% (€7.9 million) and the country remains focused on efficiencies and strategic agreements.

Focus on organic growth and value creation

After completing the integration of acquisitions, 2025 marks a turning point for Atrys, which is reviewing its portfolio to prioritize businesses with greater international projection and cash generation capacity. “Our goal is clear: to grow where we are leaders, with differential innovation and a capital structure that maximizes returns for shareholders,” says Marian Isach.